Empower Clinics Kai Medical Lab Receives Order for Up To 5,000 Covid-19 Tests from Two Film & Television Productions in Excess Of $750,000
Empower Clinics announced that its acquired Kai Medical Laboratory received a repeat order for 5,000 COVID-19 RT-PCR tests from two film and television productions, generating anticipated revenue exceeding $CAD 750,000. This follow-up order highlights the lab's consistent performance since its acquisition on October 6, 2020, with prior orders totaling over $CAD 1,000,000. With a plan to triple its size to meet growing demand in testing, Empower remains committed to expanding its services and product offerings across North America.
- New order of over $CAD 750,000 boosts revenue.
- Repeat business indicates strong customer trust and performance.
- Plans to triple Kai Medical Laboratory's size reflect growing demand.
- None.
Kai Medical Laboratory, a state-of-the-art diagnostics laboratory in Dallas, TX was acquired by Empower Clinics on October 6, 2020 to further advance the Company's COVID-19 national testing programs for enterprise clients, including movie and television studios, businesses and travel industry
VANCOUVER, BC / ACCESSWIRE / April 14, 2021 / EMPOWER CLINICS INC. (CSE:CBDT) (Frankfurt:8EC) (OTCQB:EPWCF) ("Empower" or the "Company") an integrated healthcare company - serving patients through medical centers, telemedicine platforms and a high complexity medical diagnostics laboratory processing thousands of COVID-19 specimens, is pleased to announce that Kai Medical Laboratory ("KAI") has received an order for COVID-19 RT-PCR tests that is anticipated to be in excess of $CAD 750,000 from two new film and television productions.
5,000 TEST ORDER FOR FILM & TELEVISION PRODUCTIONS REPRESENTS REPEAT ORDER BASED ON CONSISTENT PERFORMANCE OF KAI MEDICAL LAB
In early October, shortly after the acquisition of KAI, Empower announced an agreement to process approximately 1,000 COVID-19 RT-PCR tests for a major film & TV production over a 30-day period, with the possibility of more business upon successful completion of the initial tests.
On November 16, 2020 KAI received a repeat and record COVID-19 testing order for approximately 9,000 units in excess of $CAD 1,000,000 over a four-month period.
Today's announcement represents a repeat Purchase Order of approximately 5,000 units to be processed over just a two-month period. The total revenue from this order is anticipated to be in excess of $CAN 750,000.
"Our team at KAI continues to deliver the type of performance to Tier-1 clients that is worthy of significant repeat business that serves as unequivocal validation of our capabilities," said Steven McAuley, Chairman & CEO of Empower. "To this end, the magnitude of KAI's growth and success cannot be overstated as it continues to focus on very active business development and product development, setting a path toward significant North American growth in the midst of tripling its size. KAI is well on its way to becoming a national brand supported by our strong working capital position and a team dedicated to performance."
As of September 1st, KAI has already processed tests for multiple different film and television productions in key US markets including Los Angeles, Atlanta, New York, Dallas, earning the highest confidence of the industry.
KAI MEDICAL LABORATORY NOW EXPANDING TO TRIPLE CURRENT SIZE IN ANTICIPATION OF ANTICIPATED RAPID TEST GROWTH
On February 16th, Empower announced "KAI Laboratory Now Tripling in Size in Anticipation of Test Volumes by End of Q1"
KAI continues to progress on the design and build out of the laboratory expansion to prepare to meet upcoming demand in a number of areas. First, the continued processing of RT-PCR tests for film & television productions, commercial accounts and enterprise level clients. Second, the full e-commerce impact of KaiTests.com and the national direct-to-consumer marketing programs for KAI Saliva, an FDA, EUA authorized and Health Canada approved at-home Saliva COVID-19 RT-PCR Test. KAI Saliva provides travellers, both foreign and domestic with a simple, fully compliant method to obtain an RT-PCR test and test result prior to arriving or coming back into Canada and USA, or arriving in other countries that have similar executive travel orders.
Finally, KAI Labs continues the development of new direct-to-consumer test protocols that will expand the product offers on Kaitests.com throughout 2021 and beyond.
McAuley added "With each passing month Empower gains more strength and velocity in every aspect of our business from KAI Lab in Dallas to our rapidly expanding clinic operations in Canada and our direct-to-consumer products such as KAI Saliva. All of which are amply funded well into the future with our strongest balance sheet ever thanks to the receipt of more than
This press release is available on the Empower Clinics Verified Forum on AGORACOM for shareholder discussion, questions and engagement with management https://agoracom.com/ir/EmpowerClinics
ABOUT EMPOWER:
Empower is an integrated healthcare company that provides body and mind wellness for patients through its clinics, with digital and telemedicine care, and world-class medical diagnostics laboratories. Supported by an experienced leadership team, Empower is aggressively growing its clinical and digital presence across North America. Our Health & Wellness and Diagnostics & Technology business units are positioned to positively impact the integrated health of our patients, while simultaneously providing long term value for our shareholders.
ON BEHALF OF THE BOARD OF DIRECTORS:
Steven McAuley
Chief Executive Officer
CONTACTS:
Investors:
Steven McAuley CEO
s.mcauley@empowerclinics.com
604-789-2146
Investors:
Tamara Mason
Business Development & Communications
t.mason@empowerclinics.com
416-671-5617
DISCLAIMER FOR FORWARD-LOOKING STATEMENTS
This news release contains certain "forward-looking statements" or "forward-looking information" (collectively "forward looking statements") within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Forward-looking statements can frequently be identified by words such as "plans", "continues", "expects", "projects", "intends", "believes", "anticipates", "estimates", "may", "will", "potential", "proposed" and other similar words, or information that certain events or conditions "may" or "will" occur. Forward-looking statements in this news release include, but are not limited to, statements regarding: the expected benefits to the Company and its shareholders as a result of the acquisition of Kai Medical Laboratory; the transaction terms; the expected number of clinics and patients following the closing; the future potential success of Kai Medical Laboratory, Sun Valley's franchise model; launch of new healthcare centers and the occurrence thereof; that the Company can bring healthcare to millions of Canadians; that new healthcare services can be added and that the Company will be positioned to be a market- leading service provider for complex patient requirements in 2020 and beyond. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including: that Kai Medical Laboratory will successfully win any US Government RFP; that the MedX Health pilot program will be successful; that Empower will place the MedX Health teledermatology product in health centers in North America; that the Company's products may not work as expected; that the Company may not be able to expand COVID-19 testing; that legislative changes may have an adverse effect on the Company's business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; that the Company will be able to commence and/or complete build-outs and tenants improvements for Canadian clinics or Kai Medical Laboratory expansion in 2Q 2021; that general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed transaction; and other factors beyond the Company's control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.
SOURCE: Empower Clinics Inc.
View source version on accesswire.com:
https://www.accesswire.com/640339/Empower-Clinics-Kai-Medical-Lab-Receives-Order-for-Up-To-5000-Covid-19-Tests-from-Two-Film-Television-Productions-in-Excess-Of-750000
FAQ
What recent order did Empower Clinics announce for Kai Medical Laboratory?
When was Kai Medical Laboratory acquired by Empower Clinics?
How much revenue has Kai Medical Laboratory generated from COVID-19 testing?
What is the future growth plan for Kai Medical Laboratory?
What services does Empower Clinics provide?
